Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
PHILADELPHIA and LONDON, Feb. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) announced today the successful completion of the tender offer by its wholly owned subsidiary Pilgrim...
PHILADELPHIA, Feb. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) today announced that it is extending the subsequent offering period for the cash tender offer by its wholly-owned...
PHILADELPHIA and LONDON, Feb. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) announced today the expiration of the initial offering period of the tender offer by its wholly owned...
LONDON, Jan. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) (GSK) announced today that Pilgrim Acquisition Corporation, a wholly owned subsidiary of GSK, is today commencing a cash...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced consolidated financial results for the three and nine months ended September 30, 2006. Third Quarter...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting interim clinical data from an ongoing phase 1 trial of its investigational compound...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that it will report Third Quarter 2006 financial results on Thursday, November 9, 2006, before the financial...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it received the Cerep Award for Research with the greatest therapeutic potential at the 14th...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting preclinical data on its investigational compound, PPI-2458, at the 14th International...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
